GlaxoSmithKline’s (GSK) triple therapy for chronic obstructive pulmonary disease (COPD) has been approved in Europe. The licence from the European Commission means Trelegy Ellipta is now ...

GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...